Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Imagine you're about to go on a cross-country trip, stopping at spots along the way to admire local attractions.
Lung immunity is essential to combat all pulmonary diseases, including COVID-19, pneumonia, lung cancer, asthma and COPD.
Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.
Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body's own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.
A team of researchers described an innovative nanofluidic device for high-throughput preparation of exosome-based drug delivery vehicles.
Researchers performed a new study and demonstrated that stem-like T cells found in some lymph nodes could exhibit natural cancer-fighting properties.
The emergence of the COVID-19 pandemic in the United States in early 2020 left researchers struggling to identify lab models of SARS-CoV-2 infection.
A new study has discovered a two-arm molecule that can effectively deplete cancer-protecting cells within tumors.
Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.
Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.
Most of the tests that doctors use to diagnose cancer -- such as mammography, colonoscopy, and CT scans -- are based on imaging. More recently, researchers have also developed molecular diagnostics that can detect specific cancer-associated molecules that circulate in bodily fluids like blood or urine.
In a recent study, researchers investigated how natural killer cells target breast cancer using the body's own immune system.
A new study finds breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, which appears in CANCER, states that compared to the general population in the United States, the risk of new cancer diagnoses among survivors was 20% higher for those with hormone receptor (HR) positive cancers and 44% higher for those with HR-negative cancers.
Modified immune cells that ruthlessly kill cancerous tumors may prove a game-changer for people living with late-stage cancer.
Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer.
A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year.
Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.
In the United States, lung cancer is the main cause of cancer death in both male and female populations.
During biomarker testing, certain disease-associated molecules are examined to estimate the progression of a disease and its response to treatments.
The second most common neurodegenerative disorder is Parkinson’s disease, but despite this, not much is known about the causes of this condition.